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BACKGROUND: Quality of life measurement in cholangiocarcinoma and gallbladder cancer involves the assessment of patient-reported
issues related to the symptoms, disease and treatment of these tumours. This study describes the development of the disease-specific
quality of life (QoL) questionnaire for patients with cholangiocarcinoma and gallbladder cancer to supplement the European
Organization for Research and Treatment of Cancer (EORTC)-QLQ C30 core cancer questionnaire.
METHODS: Phases 1–3 of the guidelines for module development published by the EORTC were followed, with adaptations for
incorporation of questions from existing modules.
RESULTS: A total of 47 QoL issues (questions) were identified; 44 questions from the two related validated questionnaires, the EORTC
QLQ-PAN26 (pancreatic module) and the EORTC QLQ-LMC21 (liver metastases module), two from the Functional Assessment of
Cancer Therapy hepatobiliary module questionnaire in the literature search and one from healthcare professional interviews.
Following phase 1 and 2 interviews with patients (n¼101) and health care professionals (n¼6), a 23-question provisional
questionnaire was formulated. There were five questions from PAN26, 15 from LMC21 and three extra questions. In phase 3, the
provisional item list was pre-tested in 52 patients in four languages and this resulted in a 21-item module.
CONCLUSION: This is the only disease-specific QoL questionnaire for patients with cholangiocarcinoma and gallbladder cancer, and
initial assessments show it to be accurate and acceptable to patients in reflecting QoL in these diseases.
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Quality of life (QoL) measurements are increasingly being used as
endpoints in clinical trials especially those in patients with
malignant diseases (Blazeby et al, 2002). A limited amount of
research has been published about QoL in patients with
cholangiocarcinoma and gallbladder cancer, and to our knowledge
there is no disease-specific QoL score questionnaire.
Current cancer-specific QoL questionnaires are the European
Organization for Research and Treatment of Cancer (EORTC)
QLQ-C30 and the Functional Assessment of Cancer Therapy
(FACT) generic questionnaires. These are supplemented by
modules specific to different types of cancer because individual
cancers have different etiologies, symptoms, treatments and
prognosis (Blazeby et al, 2002). A FACT module for hepato-
biliary cancers (FACT-Hep) is non-specific as it is designed for
use in patients with cancer of the head of pancreas, colorectal
hepatic metastases, primary liver cancer and cholangiocarcinoma.
The EORTC QLQ-C30 does not address the specific symptoms
of cholangiocarcinoma and gallbladder cancer, so there is a
need to develop a disease-specific QoL questionnaire to supple-
ment this.
There are other generic tools to measure QoL but they do not
cover the specific issues that affect this group of patients. The
pancreatic module, the EORTC QLQ-PAN26 (Fitzsimmons et al,
1999), which has issues related to tumours solely in the pancreas
and the liver metastases module, the EORTC QLQ-LMC21
(Kavadas et al, 2003), which has issues related to liver metastases.
However, these modules separately do not address the issues
perceived by patients with cholangiocarcinoma and gallbladder
cancer.
Cancers of the biliary tree include cholangiocarcinoma and
gallbladder cancer, and are uncommon cancers, although there is
evidence that the incidence of these has increased significantly
over the last decade (McGlynn et al, 2006). In the United States,
the incidences of cholangiocarcinoma and gall bladder cancer are
1–2 (Khan et al, 2005) and 2.5 cases (Kaushik, 2001) per 100000
people per year, respectively. Cholangiocarcinoma incidence rates
vary worldwide (Khan et al, 2008). The highest rates are in
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snortheast Thailand (96 per 100000 men) (Shaib and El-Serag,
2004). These cancers lie anatomically within the liver, and between
the liver and pancreas, so issues relevant to the patients may be
contained in the existing EORTC modules for pancreatic cancer
(PAN26) (Fitzsimmons et al, 1999) and liver metastases (LMC21)
(Kavadas et al, 2003).
Cholangiocarcinoma and cancers of the bile duct historically
have been associated with poor prognosis and poor health-related
quality of life (Heffernan et al, 2002). Cholangiocarcinoma
presents a formidable challenge. The majority of patients present
with unresectable disease and have a survival of less than 12
months (Anderson et al, 2004). Colorectal liver metastases
patients have a median survival of 8 months without treatment
(Garden et al, 2006), which is longer than patients with pancreatic
cancer (4–8 months) (Yeo and Cameron, 1998) or extra-hepatic
(6 months) and intra-hepatic (4 months) cholangiocarcinoma
(Ahmed et al, 2008), implying some different issues for these
tumours.
Clinical features of cholangiocarcinoma depend on the location
of the tumour (Anderson et al, 2004). Symptoms are mainly
related to intra- or extrahepatic biliary obstruction (DeOliveira
et al, 2007; Weber et al, 2007). Intrahepatic cholangiocarcinoma
can present with a mass in the liver but can obstruct local ducts
causing fever and abscess formation. Extrahepatic cholangiocarci-
nomas cause obstruction with pruritus, jaundice and cholangitis.
Gallbladder cancer can present with pain because of a mass and
can also cause obstruction of the bile ducts by direct invasion.
Systemic symptoms of cancer are common. The symptoms are
similar to many of those present in pancreatic cancer, for example,
anorexia, jaundice and itching but also may have similarities with
symptoms of liver metastases such as right upper quadrant pain,
local abscess formation with recurrent fevers and some patients
may experience issues relating to external drains.
Treatments may be similar to both pancreatic and metastatic
liver cancer—such as surgery (DeOliveira et al, 2007), stenting,
external drainage (Patel and Singh, 2007), chemotherapy (Hong
et al, 2007) and radiotherapy (Ben David et al, 2006). It has been
difficult to show significant survival benefits of many treatments
(Malhi and Gores, 2006; Hong et al, 2007), although a recent
survival difference in two chemotherapy regimes has been
reported (Valle et al, 2010) and those that do prolong life may
actually reduce quality of life. A number of new therapies for
cholangiocarcinoma are in clinical trial stage (for example,
photodynamic therapy and new chemotherapy drugs) and it is
important to have a validated QoL questionnaire to provide
reliable data for a patient reported endpoint in these trials.
This paper describes the development of a specific module to
accompany the EORTC QLQ-C30 to assess QoL in patients with
cholangiocarcinoma and gallbladder cancer.
PATIENTS AND METHODS
Design
Guidelines for development of new modules published by the
EORTC QoL group (Blazeby et al, 2002) describe three phases of
module development: generation of issues from literature review,
interviews with patients and interviews with health care profes-
sionals; conversion of these issues into a standard format list of
items (provisional questionnaire) and initial testing in a different
group of patients. These guidelines are designed for use where
there are no existing modules for related cancers. Cholangiocarci-
noma and gallbladder cancer are closely related to tumours of the
pancreas and to liver metastases. We therefore modified phase 1 by
relying heavily on the questions from the two existing modules for
pancreas and liver metastases. Semi-structured interviews were
performed with the list of questions and the core questionnaire
QLQ-C30 as per the guidelines.
Phase 1
Identification of issues The QLQ-PAN26 and QLQ-LM21 were used
to generate a list of issues. This was supplemented by issues raised
from initial patient, and health care professional (HCP) interviews
the literature search and a review of questions from FACT-Hep.
Semi-structured interviews were performed with the list of questions
and the core questionnaire QLQ-C30 as per the EORTC guidelines,
in order to assess which questions were important, and if there were
extra issues that had not been included.
The procedure followed is summarised in Table 1.
Subjects Patients for the interviews for phase 1 were recruited
from the UK, Taiwan and Germany.
The inclusion criteria were:
(a) Age 18 years and above.
(b) Diagnosis of cholangiocarcinoma or gallbladder cancer from
histology or MDT (multidisciplinary team meeting/tumour
board) agreement based on radiology or both.
(c) Patients able to give written informed consent
(d) No history of other significant malignant disease.
(e) Patients able to understand the language of the questionnaire.
Healthcare professionals were identified who had cared for patients
with cholangiocarcinoma and gallbladder cancer.
Ethical committee permission was obtained.
Data collection In phase 1, 101 patients and 6 HCPs were asked
to rate the questions according to their relevance for quality of life
for this group of patients on a four-point Likert scale (one—not at
all, two—a little, three—quite a bit to four—very much) and to
choose Yes/No if the question should be included in the
questionnaire. They were asked if they had any other comments.
HCPs were asked to list five questions they would like included in
the questionnaire. The questions were grouped into clinically
meaningful groups so the patients could compare items more
easily, for example, the questions on eating were seen grouped
together so they could be compared and chosen for relevance.
Data analysis Descriptive statistics were used to analyse the
results of the interviews in phase 1.
Table 1 Process of development for cholangiocarcinoma and gallbladder
module
Phase Aims Process
1 Generation of QoL
issues relevant to the
selected group of patients.
1. Use all questions from
PAN26 and LMC21
2. Literature search
3. Interviews with health
care professionals
4. Patients’ interviews
5. Analysis of quantitative and
qualitative data and use of scoring
system to adapt list of issues
2 Construction of a
provisional questionnaire
1. Consultation of EORTC
QoL group item database
2. Construction of new items
3. Translation of provisional
questionnaire
3 Pretesting to identify and
solve potential problems
1. Interview including administration
of questionnaire to patients
2. Quantitative and qualitative
data analysis
3. Modification of questionnaire
4. Formal development report
reviewed by EORTC QoL group
Abbreviations: EORTC¼European Organization for Research and Treatment of
Cancer; QoL¼quality of life.
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sSemi-structured interviews were performed (at differing times
before, during or after treatment) with the list of questions and the
core questionnaire QLQ-C30. Patients were asked to respond to the
questionnaire on how they have felt in the past week based on their
total experience as result of illness and treatments.
Phase 2: Selection of items
The questions were prioritised for inclusion based on an arbitrary
scoring system. Table 2 lists the four categories where each carries
a score of 0 or 1 and these were added to give a total score.
Questions with total scores of 3 or more were provisionally
included. Then the final decision was made after analysing
comments made by the patients and HCPs.
Phase 3: Pretesting
Patients were recruited from UK, Taiwan, Germany and Italy. The
inclusion criteria were as for phase 1.
Recruitment was designed to interview at least 50 patients with
the modified questionnaire and to have a reasonable spread of
patients with intrahepatic, extrahepatic cholangiocarcinoma and
gallbladder disease. It was also planned to have three treatment
groups with 10–15 patients recruited per group. The treatment
groups were surgery, chemotherapy/radiotherapy and supportive
care including stent insertion/external drains.
In Phase 3, the Likert scores were assessed according to level
of symptoms in 52 patients.
The ratings for relevance by mean Likert scores were linearly
transformed to a 0–100 scale, with ‘not at all’ corresponding
to 0 and ‘very much’ to 100 (for example, pretransformed score
2¼33.3 on ‘transformed’ score) (Garden et al, 2006). Items with
mean scores of less than 25 were considered for deletion, but
retained if clinically appropriate and either patients or professionals
considered them sufficiently important to test further. Ranges were
examined to ensure a reasonable spread of scores.
Patients were asked to complete six debriefing questions and
were asked if any of the questions were difficult, annoying, confusing,
upsetting, intrusive or irrelevant. They were asked if there were
any questions that they thought were relevant but not included in
the provisional questionnaire and if they had any other comments.
Construct validity was assessed by discriminant validity and conver-
gent validity by Pearson’s correlation. To explore convergent validity
correlation between items and scales was performed. For investigating
discriminant validity, correlation between single items and other scales
were calculated. Criterion validity refers to how well one variable or set
of variables predicts an outcome based on information from other
variables. This can be achieved by known group comparisons and these
were curative vs noncurative intent and performance status.
RESULTS
Phases 1 and 2
Literature search Literature searches were performed in five databases
(Medline, Embase, Cinhal, AMED and Psych Info) to locate relevant
articles. Quality of life was linked with the following number of articles:
cholangiocarcinoma (43), gallbladder cancer (0) and pancreatic cancer
(28). A manual search of relevant issues within these papers was done,
as well as a search within the alternative questionnaires. From that, a
provisional list of 47 questions and issues was made.
Interviews with HCPs Six HCPs (one gastroenterologist, one
hepatologist, one registrar, two nurse specialists and one nursing
sister from hospice) were interviewed.
There were 18 questions that HCPs selected for inclusion in the
module. Health care professionals rated each question’s relevance
and wanted nine questions to be included. These were taken into
account in the scoring system (Table 2).
Interviews with patients Clinical details of the patients are shown
in Table 3.
Table 2 Scoring system for selection of items in phase 1
Scoring criteria for questions Threshold Score
Mean of patients’ Likert score 41.5 1 (0 for o1.5)
o20% patients said no to inclusion 420% 1 (0 for420%)
o30% HCP said no to inclusion 430% 1 (0 for 430%)
HCP said include in top 5 1
Abbreviation: HCP¼health care professional.
Table 3 Demographic and clinical details of patients in Phases 1–3
Demographics Phase 1 and 2, n¼101 Phase 3, n¼52
Country of recruitment (%) Germany 21 (21) Germany 5 (10)
Taiwan 4 (4) Italy 3 (6)
UK 76 (75) Taiwan 10 (19)
UK 34 (65)
Age (years) Mean (s.d.) 64 (12) Mean (s.d.) 67 (8.3)
Median 67 Median 67
Range 28–87 Range 50–80
Male (%) 51 (50.4) 25 (48)
Site (%) Intrahepatic 36 (36) Intrahepatic 24 (46)
Proximal extrahepatic
a 31 (31) Proximal extrahepatic
a 14 (27)
Distal extrahepatic
a 13 (12) Distal extrahepatic
a 5 (10)
Gallbladder 21 (21) Gallbladder 8 (15)
Unknown 0 (0) Unknown 1 (2)
Treatment (%) 1. Surgery 42 (42) 1. Surgery 22 (42)
2. Chemotherapy and/or
radiotherapy (including PDT)
44 (44) 2. Chemotherapy
and/or radiotherapy
25 (48)
3. Supportive care includes:
stent insertion
54 (54) 3. Supportive care includes
external drain/stent insertion
51 (98)
Karnofsky status before treatment Mean (s.d.) 74 (16) Mean (s.d.) 73 (15.4)
Median 80 Median 80
Range 20–100 Range 40–100
aProximal extrahepatic¼above cystic duct and distal extrahepatic¼below cystic duct.
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sThere was a representative spread of patients with intrahepatic
vs extrahepatic disease as well as a reasonable number of patients
with gallbladder cancers. Patients were recruited into three
treatment groups (at least 10–15 per group) and this was in
similar proportions as that seen in clinical practice. Some patients
had more than one treatment so the total percentage for all
treatments was more than 100%. Patients were interviewed (many
recently diagnosed) between 1–72 months from diagnosis with
mean of 8.9 and median of 3.5 months.
Analysis, adaptation and production of the provisional question-
naire A total of 47 QoL issues were generated from the related
validated questionnaires PAN26 and LMC21, literature search and
HCP interviews. A total of 44 existing items were used, as three
replicates were excluded. Existing questions were used except for
the question on jaundice. The new question ‘Have you been
worried about your skin being yellow?’ was generated from HCP
interviews, but an equivalent question from the EORTC QoL item
bank could not be found. There were three extra issues that were
included, the question about jaundice and two questions from the
FACT-hep questionnaire ‘Did you have fevers?’ and ‘Did you have
any difficulties with drainage tubes/bags?’
Questions/issues were deleted on the basis of the scoring system
after taking into account comments made by patients’ and HCPs,
to form the provisional item list to be used in Phase 3.
Questions were deleted: one each from eating and jaundice
scales, five from the relationship scale, two from the pain scale,
three from the body image scale, both questions from the bowel
scale, two from the satisfaction scale and six single items.
The question on fevers was kept in because of scoring and was
highlighted as important by HCPs and patients. The question on
tubes and bags was included as HCPs thought it was clinically
relevant.
This led to the number of items being reduced from 47 to 23.
Five questions from PAN26, 15 from LMC21 and 3 extra questions
formed a provisional list of 23 items.
The items were grouped into five scales of eating, jaundice,
tiredness, pain and anxiety and five additional items, which did
not fit into the scales.
The questions were translated according to QoL Group
translation guidelines into Chinese Mandarin, Italian and German
(Dewolf et al, 2009).
Phase 3: pretesting the provisional item list Pretesting interviews
were performed using the provisional questionnaire of 23
questions together with the QLQ-C30 on patients (n¼52) from
the UK, Taiwan, Germany and Italy.
Linear transformation of Likert scores are listed below, in
Table 4, with items that scored o25 highlighted in red. Debriefing
questions were completed by 52 patients and 15 comments were
made. These included support for questions on jaundice and
tubes/bags, but no specific comments relating to possible deletion
of questions. Other comments made by more than one patient in
these interviews were that jaundice had a big impact on QoL, and
that family and emotional issues were considered important.
All questions had ranges from 1 to 4 and had no obvious ‘floor’
or ‘ceiling’ effects, which would necessitate deletion.
On the basis of interviews and descriptive statistics, two
questions were deleted. These were single item questions F1 (had
fevers) and L46 (trouble talking about feelings to family or
friends). Question F2 (difficulties with drainage tubes/bags) was
kept in the questionnaire even though the ‘transformed’ mean
score waso25 because clinical opinion suggested this was an
important question for the relatively few patients who have tubes
or bags. Question X in the jaundice scale (worried about skin being
yellow) was kept in, even though the ‘transformed’ mean score was
o25. This was because Cronbach’s alpha for the jaundice scale
(with question X removed) decreased to an unacceptable figure
of 0.58 from an acceptable figure of 0.78 (with question X
included). This may be because this question is applicable for only
some patients, but for those patients suffering from jaundice the
question was very important. The new questionnaire has 21 items
and is called the EORTC QLQ-BIL21. It has five multi-item scales:
eating (four items); jaundice (three items); tiredness (three items);
pain (four items) and anxiety (four items) and three single items
about treatment side effects, drainage tubes/bags and worried
about losing weight.
Although the number of patients interviewed was limited,
psychometric analysis was performed with following results.
Construct validity
This was assessed by Pearson’s correlation.
For convergent validity, all the named scales and related
questions had significant correlations of rX0.40, which shows
the questions in the named scales are measuring the same
construct and working well together.
For discriminant validity all correlations were less than 0.40.
This shows items were not highly correlated with other scales as
expected as different scales are measuring different groups of
issues. Correlations between scales were also less than 0.40, which
confirmed the scales were measuring defined groups of issues.
There was no strong correlation between scales in the core
module and new module.
Criterion validity
This was assessed by known group comparisons:
1. Patients treated with curative intent (surgery) were compared
those with noncurative intent (stent insertion, chemotherapy,
radiotherapy). Treatment with curative intent was associated
with significantly lower mean scores for jaundice (12 vs 32), pain
(19 vs 37), single item – worried about losing weight (9 vs 29) and
anxiety (borderline at 41 vs 56) with noncurative intent.







L31-trouble eating Eating 52 27.6 30.0
L32-fullness after eating Eating 51 37.9 30.6
L34-taste problems Eating 51 24.8 31.2
P36-restricted in food intake Eating 51 30.7 30.4
L41-skin/eyes yellow Jaundice 51 26.1 38.5
P44-had itching Jaundice 51 23.5 32.9
X-worried skin yellow Jaundice 50 17.3 30.3
L37-less active Tired 51 60.1 32.0
L43-slowed down Tired 51 58.2 30.0
L44-lacking in energy Tired 51 62.1 29.9
P34-pain at night Pain 51 30.1 32.1
L39-pain in stomach Pain 51 28.1 30.8
L42-pain in back Pain 51 26.8 32.7
P32-bloating in abdomen Pain 51 35.9 33.2
L47-felt stressed Anxiety 51 34.6 29.0
L48-less able to enjoy yourself Anxiety 50 57.3 33.7
L49-worried about future health Anxiety 51 54.9 32.5
L50-worried about family in future Anxiety 51 54.2 38.9
P50-treatment side effects Single item 51 39.9 35.3
F1-had fevers Single item 51 17.0 28.6
F2-difficulties with drainage bags/tubes Single item 49 17.7 30.5
L46-trouble talking about feelings
to family/friends
Single item 51 19.0 26.9
L33-worried about losing weight Single item 51 27.5 31.8
Those in italics were considered for deletion—see text.
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s2. Performance status was correlated to each scale and was
significantly related to the scales eating (mean score for
Karnofsky o70, 46 vs 22 for X70), jaundice (mean score
for Karnofsky o70, 35 vs 15 for X70), tiredness (mean
score for Karnofsky o70, 78 vs 50 for X70) and two single
items (difficulties with drainage tubes and treatment side
effects) (mean score for Karnofsky o70, 50 vs 20 for X70).
Internal consistency
This was assessed using Cronbach’s alpha coefficient, which was
40.70 for the proposed scales indicating good internal consistency
(Table 5).
DISCUSSION
The EORTC QLQ-BIL21 (in Table 6) is a disease-specific module
for patients with cholangiocarcinoma and gallbladder cancer to be
used in addition to the core questionnaire EORTC QLQ-C30.
Together, these questionnaires assess all aspects of health-related
QoL in these patients. The QLQ-BIL21 assesses issues related to
disease, treatment and emotional wellbeing, which are not covered
by the QLQ-C30. It has been developed using adapted EORTC
module development guidelines, see Table 1.
As the clinical symptoms, treatment and prognosis of cholan-
giocarcinoma are closely related to those of pancreatic cancer and
liver metastases, it was possible to develop this module by
combination of relevant items from existing modules for pancreas
cancer (PAN26) and liver metastases (LMC21). In addition, issues
raised from initial patient and HCP interviews, and the literature
search were included.
The QLQ-BIL21 has five questions from PAN26, 14 from LMC21
and 2 extra questions (one from FACT-Hep and one from HCP
interviews). The QLQ-BIL21 has been pretested in four languages
(three in Europe, one in Asia). Our study has shown that the QLQ-
BIL21 is relevant, acceptable and applicable to patients in different
countries and cultures. The questionnaire appears in our
preliminary testing to have high construct and convergent validity
as well as good reliability and internal consistency. All these
features will require confirmation in a Phase 4 field test.
Generally, cholangiocarcinoma and gallbladder cancer are not
detected until late in the disease course, thus significant symptoms
and QoL issues rapidly develop. This is reflected in the issues
captured in the questionnaire. Patients score very highly on the
tiredness and the anxiety scales, which seem to affect the majority
of patients. As cholangiocarcinomas can be small but can cause
obstruction of bile ducts, the issues around jaundice are parti-
cularly relevant. Gallbladder cancers are often larger and may have
a mass effect, leading to pain and jaundice. The systemic symptoms of
cancer were common in this group of patients and in particular those
described in the eating scale. The question on difficulty with drainage
tubes did not score highly but was very important to patients who
experienced this, and clinical opinion reinforced this. Bile-duct cancer
in particular often requires treatment with percutaneous drainage
tubes, which reinforces the need for a specific module for this tumour
type. The question on side effectso ft r e a t m e n ts c o r e dh i g h l yw i t h
patients, thus, both quality and quantity of life are important factors
when deciding on treatments, hence, assessment of QoL is needed to
j u s t i f yt h eu s eo ft h e s et h e r a p i e s .
There were some limitations of the study. Cholangiocarcinoma
and gallbladder cancer are less common diseases so it was difficult
to recruit large numbers of patients in a reasonable timescale. In
all, 100 patients were recruited in phase 1 and 2 (as with
modification to the guidelines, it was felt appropriate to include a
large number of patients at this stage) and 50 patients in phase 3.
These numbers are comparable with many other published phase 3
studies of module development and are consistent with the
guidelines for module development (Valle et al, 2010). The
psychometric evaluations would normally be done on a larger
cohort of patients but the results imply good results for this
sample. The patients in phase 3 were described as receiving
treatment in three separated but overlapping groups: (1) surgery,
(2) chemotherapy and radiotherapy and (3) supportive care,
including external drains and stent insertion. Many patients
received more than one treatment as is shown in Table 3 and the
distribution of these treatments in phase 3 patients is comparable
with that seen in clinical practice, suggesting our sample is
appropriate for development of a clinically relevant module. This
preliminary analysis will be confirmed later in the phase 4 study
with a larger international sample. More European than Asian
patients were included for phases 1–3, but the higher incidence in
Asia will necessitate higher percentage recruitment from Asia in
phase 4. Another limitation is that, although a number of HCPs
from different fields were selected for interview for phase 1, these
did not include oncologist, radiologist or surgeon.
The EORTC QLQ-BIL21 questionnaire will now undergo
international field-testing to confirm the reliability, validity and
cross-cultural applicability.







Table 6 EORTC QLQ-BIL21









31. Have you had trouble with eating? 1 2 3 4
32. Have you felt full up too
quickly after beginning to eat?
123 4
33. Have you had problems
with your sense of taste?
123 4
34. Were you restricted in the
types of food you can eat as a
result of your disease or treatment?
123 4
35. Have your skin or eyes
been yellow (jaundiced)?
123 4
36. Have you had itching? 1 2 3 4
37. Have you been worried
about your skin being yellow
123 4
38. Have you been less active
than you would like to be?
123 4
39. Have you felt ‘slowed down’? 1 2 3 4
40. Have you felt lacking in energy? 1 2 3 4
41. Did you have pain during the night? 1 2 3 4
42. Have you had pain in your stomach area? 1 2 3 4
43. Have you had pain in your back? 1 2 3 4
44. Did you have a bloated
feeling in your abdomen?
123 4
45. Have you felt stressed? 1 2 3 4
46. Have you felt less able to enjoy yourself? 1 2 3 4
47. Have you worried about
your health in the future?
123 4
48. Were you worried about
your family in the future?
123 4
49. To what extent have you been troubled
with side-effects from your treatment?
123 4
50. Have you had difficulties
with drainage tubes/bags?
123 4
51. Have you worried about losing weight? 1 2 3 4
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This questionnaire that is specific for use in patients with
cholangiocarcinoma and gallbladder cancer will supplement the
QLQ-C30 and should detect small changes in QoL because of
disease progression or treatments.
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